These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29378238)

  • 1. Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
    Han B; Cai J; Gao W; Meng X; Gao F; Wu P; Duan C; Wang R; Dinislam M; Lin L; Kang C; Jiang C
    Cancer Lett; 2018 Apr; 419():280-290. PubMed ID: 29378238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
    Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
    Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
    Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB.
    Aasland D; Götzinger L; Hauck L; Berte N; Meyer J; Effenberger M; Schneider S; Reuber EE; Roos WP; Tomicic MT; Kaina B; Christmann M
    Cancer Res; 2019 Jan; 79(1):99-113. PubMed ID: 30361254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UBE2C enhances temozolomide resistance by regulating the expression of p53 to induce aerobic glycolysis in glioma.
    Zhou K; Wang D; Du X; Feng X; Zhu X; Wang C
    Acta Biochim Biophys Sin (Shanghai); 2024 Jun; 56(6):916-926. PubMed ID: 38634120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.
    Reich TR; Schwarzenbach C; Vilar JB; Unger S; Mühlhäusler F; Nikolova T; Poplawski A; Baymaz HI; Beli P; Christmann M; Tomicic MT
    Cell Mol Life Sci; 2021 Jul; 78(14):5587-5604. PubMed ID: 34100981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
    Lu Y; Kwintkiewicz J; Liu Y; Tech K; Frady LN; Su YT; Bautista W; Moon SI; MacDonald J; Ewend MG; Gilbert MR; Yang C; Wu J
    Cancer Res; 2017 Apr; 77(7):1709-1718. PubMed ID: 28202508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
    Bao Z; Chen L; Guo S
    J Cell Biochem; 2019 Jun; 120(6):10205-10214. PubMed ID: 30592329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of KDM4A-mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis.
    Li XX; Xu JK; Su WJ; Wu HL; Zhao K; Zhang CM; Chen XK; Yang LX
    Kaohsiung J Med Sci; 2024 Feb; 40(2):161-174. PubMed ID: 37873881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Andrographolide sensitizes glioma to temozolomide by inhibiting DKK1 expression.
    Zhang ZS; Gao ZX; He JJ; Ma C; Tao HT; Zhu FY; Cheng YN; Xie CQ; Li JQ; Liu ZZ; Hou LL; Sun H; Xie SQ; Fang D
    Br J Cancer; 2024 Nov; 131(8):1387-1398. PubMed ID: 39266624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death.
    He Y; Roos WP; Wu Q; Hofmann TG; Kaina B
    Mol Cancer Res; 2019 May; 17(5):1129-1141. PubMed ID: 30796178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents.
    Lang F; Cornwell JA; Kaur K; Elmogazy O; Zhang W; Zhang M; Song H; Sun Z; Wu X; Aladjem MI; Aregger M; Cappell SD; Yang C
    Neuro Oncol; 2024 Jun; 26(6):1083-1096. PubMed ID: 38134889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
    Zhang X; Yu J; Zhao C; Ren H; Yuan Z; Zhang B; Zhuang J; Wang J; Feng B
    Biomed Pharmacother; 2019 Jan; 109():2192-2202. PubMed ID: 30551476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.
    Qin T; Mullan B; Ravindran R; Messinger D; Siada R; Cummings JR; Harris M; Muruganand A; Pyaram K; Miklja Z; Reiber M; Garcia T; Tran D; Danussi C; Brosnan-Cashman J; Pratt D; Zhao X; Rehemtulla A; Sartor MA; Venneti S; Meeker AK; Huse JT; Morgan MA; Lowenstein PR; Castro MG; Yadav VN; Koschmann C
    Cell Rep; 2022 Jan; 38(2):110216. PubMed ID: 35021084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stalled replication forks within heterochromatin require ATRX for protection.
    Huh MS; Ivanochko D; Hashem LE; Curtin M; Delorme M; Goodall E; Yan K; Picketts DJ
    Cell Death Dis; 2016 May; 7(5):e2220. PubMed ID: 27171262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.
    George SL; Lorenzi F; King D; Hartlieb S; Campbell J; Pemberton H; Toprak UH; Barker K; Tall J; da Costa BM; van den Boogaard ML; Dolman MEM; Molenaar JJ; Bryant HE; Westermann F; Lord CJ; Chesler L
    EBioMedicine; 2020 Sep; 59():102971. PubMed ID: 32846370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.